Printer Friendly

Behring Diagnostics GmbH announces new structure of its global diagnostics business.

FRANKFURT, Germany--(HealthWire)--Jan. 13, 1997--Behring Diagnostics GmbH, today announced the new organizational structure of the global diagnostics business within the Hoechst Group Life Sciences Business. As noted in a press release issued in late December by Hoechst, effective January 1, 1997, Behring Diagnostics GmbH is the new management company for the diagnostics business within the Hoechst Group's life sciences business. Hoechst Marion Roussel, Behring Diagnostics, Hoechst Roussel Vet, and AgrEvo make up the Hoechst Group's life sciences business.

Behring Diagnostics GmbH will be the shareholder of the company's existing and to be established diagnostics companies throughout the world.

The Board of Management, designated by the Hoechst Board of Management, for Behring Diagnostics GmbH includes: Uwe Bicker, MD, PhD, chairman; Friedhelm Blobel, PhD, chief technology officer and head of the global Product Supply Organization (PSO); and Reiner Gleiss, who has been appointed chief financial and administrative officer. Mr. Gleiss has held various positions within the Hoechst organization.

"Our strengthened position within the Hoechst Group provides us an opportunity to better manage our global business while remaining focused on the needs of our customers, and the breadth of our product offering," stated Uwe Bicker, MD, PhD, chairman of Behring Diagnostics GmbH. "We will continue to concentrate on developing new ways to streamline and strengthen our business as we embark on a new era as a leader in global diagnostics."

Reporting to the Chairman, Uwe Bicker, are: Sue Andrews, head of global marketing and head of Europe region I; Charlotte Dexter, corporate communications officer; Heinz Heuser, head of Europe region II; Norbert Madry, PhD, strategy and business process development; John Sullivan, president and CEO of Behring Diagnostics Inc. and head of worldwide business development, and acting head of the Americas region; and Bob Wolf, head of the Asia-Pacific/Middle East region.

Reporting to Friedhelm Blobel are heads of the business lines and global functions of the PSO including: Harmut Hampl, PhD, microbiology; Werner Hampl, OPUS(R); David Kuhn, Emit(R); Erwin Metzmann, PhD, plasma proteins; Hermann Pelzer, PhD, coagulation; Steve Abbott, PhD, global quality systems; Hans-Joachim Fink, PhD, instrumentation; Rita Hofberg, technical product management; Yorck Koehn, logistics; Jerry Rosenstock, Esq., in the United States, patents and licensing; Ted Ullman, PhD, acting head of research; and Guenther Veith, site management Marburg.

Reporting to the Chief Financial and Administrative Officer, Reiner Gleiss, will be the functions of: finance, controlling, treasury, human resources, legal and administration. The positions and reporting lines will be announced during the first quarter of 1997.

Behring Diagnostics GmbH, the in vitro diagnostics company of the Hoechst Group, is one of the four life sciences businesses of the Hoechst Group. Hoechst Marion Roussel, Behring Diagnostics, Hoechst Roussel Vet, and AgrEvo make up the life sciences business of the Hoechst Group.

With headquarters in Frankfurt, Germany, Behring Diagnostics GmbH, manufactures and markets in vitro diagnostic systems used by healthcare professionals in hospitals and laboratories throughout the world. The company has five business lines: plasma proteins, coagulation and microbiology, based in Marburg, Germany; the OPUS(R) business line, located in Westwood, Massachusetts; and the Syva(R) business line, based in San Jose, California. Behring Diagnostics acquired the former Syva Company in 1995. Behring Diagnostics had consolidated net sales of DM 1.027 billion, in 1995, and employs approximately 3,000 worldwide.

OPUS, Syva and Emit are registered trademarks of Behring Diagnostics GmbH.

CONTACT: Behring Diagnostics, Frankfurt

Charlotte Dexter, +44 (171) 384-3390 or

+1 (800) 223-7982, box 9778
COPYRIGHT 1997 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1997, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 13, 1997
Previous Article:FIRSTPLUS FINANCIAL announces major marketing campaign with Turner Broadcasting.
Next Article:BNN Corp. reports preliminary record earnings for the quarter and year ended Dec. 31, 1996.

Related Articles
Behring Diagnostics' Cardiac Marker Assay Receives US Marketing Clearance; New Cardiac Troponin I Assay will Provide Results in 22 Minutes.
Behring Diagnostics Launches the Behring Coagulation Timer (BCT System) in the United States.
Behring Diagnostics Executive on TAM Flight.
Behring Diagnostics Names New General Manager in France.
Behring Diagnostics Establishes Legal Entities in Several European Countries.
Diagnostic Products and Dade Behring Alliance Awarded Novation Immunochemistry Contract.
Dade Behring Announces Time Change for SG Cowan Global Health Care Conference Presentation On November 14, 2002.
Vital Scientific, Dade Behring Enter Exclusive Agreement for New Specialty Drug Analyzer.
Dade Behring and Virion/Serion Sign a Non-Exclusive Distribution Agreement for Infectious Disease Diagnostics.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters